(18.189.170.206)
Users online: 3826     
Ijournet
Email id
 

Indian Journal of Clinical Anaesthesia
Year : 2018, Volume : 5, Issue : 3
First page : ( 423) Last page : ( 430)
Print ISSN : 2394-4781. Online ISSN : 2394-4994.
Article DOI : 10.18231/2394-4994.2018.0079

Effects of intravenous dexmedetomidine on 0.5% hyperbaric bupivacaine spinal anesthesia-a placebo controlled randomized trial

Thakuria Ruma1, Borah Tridip Jyoti2,*, Sonowal Jaideep3, Choudhury Dipika4

1Senior Resident, Dept. of Anesthesiology, All India Institute of Medical Sciences, New Delhi

2Assistant Professor, Dept. of Anesthesiology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya

3Senior Resident, Dept. of Anesthesiology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Shillong, Meghalaya

4Professor and HOD, Dept. of Anesthesiology, Gauhati Medical College and Hospital, Guwahati, Assam, India

*Corresponding Author: Email: tridipborah2@rediffmail.com

Online published on 3 January, 2019.

Abstract

Introduction and Aim

Dexmedetomidine, a neuraxial adjuvant, when given intrathecally with hyperbaric bupivacaine provides stable hemodynamic conditions, good quality of intraoperative and prolonged postoperative analgesia with minimal side effects. When intravenous dexmedetomidine is used in conjunction with neuraxial anesthesia, few studies have shown that it prolongs the sensory-motor blockade and provides better intraoperative and postoperative analgesia. We formulated this hypothesis that intravenous (IV) dexmedetomidine bolus followed by infusion would prolong the duration of subarachnoid block (SAB) with 0.5% heavy bupivacaine. Our aim was to assess the onset and duration of sensory and motor blockade following IV dexmedetomidine supplementation after SAB.

Materials and Methods

Sixty American Society of Anesthesiologists Grade I and II patients undergoing elective surgeries under spinal anesthesia were randomized into two groups of 30 each. Immediately after subarachnoid block with 3 ml of 0.5% hyperbaric bupivacaine, patients in group II received a loading dose of 1 μg/kg of dexmedetomidine intravenously by infusion pump over 10 min followed by a maintenance dose of 0.5 μg/kg/hr till the end of surgery, whereas patients in group I received an equivalent quantity of normal saline. The time to reach peak sensory block level, time taken for two segment regression and maximum motor block, total duration of sensory and motor blockade, Ramsay sedation score and modified Bromage score were statistically analyzed using Statistical Package for Social Sciences (SPSS Inc. Chicago, IL, USA) Windows-based version 16.0.

Results

Two segment regression time of sensory blockade was more in the dexmedetomidine group (130.33±14.49 mins) as compared to the normal saline group (94.67±15.02 mins) which was statistically significant (P< 0.0001). The duration of both sensory (277.67±24.73 mins vs. 173.67±12.45 mins) and motor blockade (206±23.72 mins vs. 135±13.83 mins) was more in the dexmedetomidine group than the normal saline group (P <0.0001).

Conclusion

The results of the present study shows that, intravenous dexmedetomidine given as a loading dose followed by maintenance dose prolonged the duration of sensory and motor blockade of bupivacaine-induced spinal anesthesia. It also provided conscious sedation without respiratory depression while maintaining good hemodynamic stability.

 

Top

Keywords

Intravenous dexmedetomidine, Spinal anesthesia, 0.5% bupivacaine.

Top

 
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
750,808,213 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.